Inhibitor	B:C0014432
Selectivity	O
for	O
Cyclin-	O
Dependent	I:C0255652
Kinase	I:C0255652
7	I:C0255652
:	O
A	O
Structural	O
,	O
Thermodynamic	O
,	O
and	O
Modelling	O
Study	O
.	O

Inhibitor	O
Selectivity	O
for	O
Cyclin-	B:C0255652
Dependent	I:C0255652
Kinase	I:C0255652
7	I:C0255652
:	O
A	O
Structural	O
,	O
Thermodynamic	O
,	O
and	O
Modelling	O
Study	O
.	O

Inhibitor	O
Selectivity	O
for	O
Cyclin-	O
Dependent	I:C0255652
Kinase	I:C0255652
7	I:C0255652
:	O
A	O
Structural	B:C0678594
,	O
Thermodynamic	O
,	O
and	O
Modelling	O
Study	O
.	O

Inhibitor	O
Selectivity	O
for	O
Cyclin-	O
Dependent	I:C0255652
Kinase	I:C0255652
7	I:C0255652
:	O
A	O
Structural	O
,	O
Thermodynamic	O
,	O
and	O
Modelling	B:C0600115
Study	O
.	O

Inhibitor	O
Selectivity	O
for	O
Cyclin-	O
Dependent	I:C0255652
Kinase	I:C0255652
7	I:C0255652
:	O
A	O
Structural	O
,	O
Thermodynamic	O
,	O
and	O
Modelling	O
Study	B:C2603343
.	O

Deregulation	B:C1516331
of	I:C1516331
the	I:C1516331
cell	I:C1516331
cycle	I:C1516331
by	O
mechanisms	O
that	O
lead	O
to	O
elevated	O
activities	O
of	O
cyclin-	O
dependent	I:C0243045
kinases	I:C0243045
(	O
cyclin	O
-	I:C0243045
dependent	I:C0243045
kinases	I:C0243045
)	O
is	O
a	O
feature	O
of	O
many	O
human	O
diseases	O
,	O
cancer	O
in	O
particular	O
.	O

Deregulation	O
of	I:C1516331
the	I:C1516331
cell	I:C1516331
cycle	I:C1516331
by	O
mechanisms	O
that	O
lead	O
to	O
elevated	O
activities	O
of	O
cyclin-	B:C0243045
dependent	I:C0243045
kinases	I:C0243045
(	O
cyclin	O
-	I:C0243045
dependent	I:C0243045
kinases	I:C0243045
)	O
is	O
a	O
feature	O
of	O
many	O
human	O
diseases	O
,	O
cancer	O
in	O
particular	O
.	O

Deregulation	O
of	I:C1516331
the	I:C1516331
cell	I:C1516331
cycle	I:C1516331
by	O
mechanisms	O
that	O
lead	O
to	O
elevated	O
activities	O
of	O
cyclin-	O
dependent	I:C0243045
kinases	I:C0243045
(	O
cyclin	B:C0243045
-	I:C0243045
dependent	I:C0243045
kinases	I:C0243045
)	O
is	O
a	O
feature	O
of	O
many	O
human	O
diseases	O
,	O
cancer	O
in	O
particular	O
.	O

Deregulation	O
of	I:C1516331
the	I:C1516331
cell	I:C1516331
cycle	I:C1516331
by	O
mechanisms	O
that	O
lead	O
to	O
elevated	O
activities	O
of	O
cyclin-	O
dependent	I:C0243045
kinases	I:C0243045
(	O
cyclin	O
-	I:C0243045
dependent	I:C0243045
kinases	I:C0243045
)	O
is	O
a	O
feature	O
of	O
many	O
human	B:C0086418
diseases	O
,	O
cancer	O
in	O
particular	O
.	O

Deregulation	O
of	I:C1516331
the	I:C1516331
cell	I:C1516331
cycle	I:C1516331
by	O
mechanisms	O
that	O
lead	O
to	O
elevated	O
activities	O
of	O
cyclin-	O
dependent	I:C0243045
kinases	I:C0243045
(	O
cyclin	O
-	I:C0243045
dependent	I:C0243045
kinases	I:C0243045
)	O
is	O
a	O
feature	O
of	O
many	O
human	O
diseases	B:C0012634
,	O
cancer	O
in	O
particular	O
.	O

Deregulation	O
of	I:C1516331
the	I:C1516331
cell	I:C1516331
cycle	I:C1516331
by	O
mechanisms	O
that	O
lead	O
to	O
elevated	O
activities	O
of	O
cyclin-	O
dependent	I:C0243045
kinases	I:C0243045
(	O
cyclin	O
-	I:C0243045
dependent	I:C0243045
kinases	I:C0243045
)	O
is	O
a	O
feature	O
of	O
many	O
human	O
diseases	O
,	O
cancer	B:C0006826
in	O
particular	O
.	O

We	O
identified	O
small	B:C1328819
-	I:C1328819
molecule	I:C1328819
inhibitors	O
that	O
selectively	O
inhibit	O
CDK7	O
,	O
the	O
kinase	O
that	O
phosphorylates	O
cell	O
-	I:C0007586
cycle	I:C0007586
CDKs	O
to	O
promote	O
their	O
activities	O
.	O

We	O
identified	O
small	O
-	I:C1328819
molecule	I:C1328819
inhibitors	B:C0014432
that	O
selectively	O
inhibit	O
CDK7	O
,	O
the	O
kinase	O
that	O
phosphorylates	O
cell	O
-	I:C0007586
cycle	I:C0007586
CDKs	O
to	O
promote	O
their	O
activities	O
.	O

We	O
identified	O
small	O
-	I:C1328819
molecule	I:C1328819
inhibitors	O
that	O
selectively	O
inhibit	O
CDK7	B:C0255652
,	O
the	O
kinase	O
that	O
phosphorylates	O
cell	O
-	I:C0007586
cycle	I:C0007586
CDKs	O
to	O
promote	O
their	O
activities	O
.	O

We	O
identified	O
small	O
-	I:C1328819
molecule	I:C1328819
inhibitors	O
that	O
selectively	O
inhibit	O
CDK7	O
,	O
the	O
kinase	B:C0031727
that	O
phosphorylates	O
cell	O
-	I:C0007586
cycle	I:C0007586
CDKs	O
to	O
promote	O
their	O
activities	O
.	O

We	O
identified	O
small	O
-	I:C1328819
molecule	I:C1328819
inhibitors	O
that	O
selectively	O
inhibit	O
CDK7	O
,	O
the	O
kinase	O
that	O
phosphorylates	B:C0031715
cell	O
-	I:C0007586
cycle	I:C0007586
CDKs	O
to	O
promote	O
their	O
activities	O
.	O

We	O
identified	O
small	O
-	I:C1328819
molecule	I:C1328819
inhibitors	O
that	O
selectively	O
inhibit	O
CDK7	O
,	O
the	O
kinase	O
that	O
phosphorylates	O
cell	B:C0007586
-	I:C0007586
cycle	I:C0007586
CDKs	O
to	O
promote	O
their	O
activities	O
.	O

We	O
identified	O
small	O
-	I:C1328819
molecule	I:C1328819
inhibitors	O
that	O
selectively	O
inhibit	O
CDK7	O
,	O
the	O
kinase	O
that	O
phosphorylates	O
cell	O
-	I:C0007586
cycle	I:C0007586
CDKs	B:C0243045
to	O
promote	O
their	O
activities	O
.	O

To	O
investigate	O
the	O
selectivity	O
of	O
these	O
inhibitors	B:C0014432
we	O
used	O
a	O
combination	O
of	O
structural	O
,	O
biophysical	O
,	O
and	O
modelling	O
approaches	O
.	O

To	O
investigate	O
the	O
selectivity	O
of	O
these	O
inhibitors	O
we	O
used	O
a	O
combination	O
of	O
structural	B:C0678594
,	O
biophysical	O
,	O
and	O
modelling	O
approaches	O
.	O

To	O
investigate	O
the	O
selectivity	O
of	O
these	O
inhibitors	O
we	O
used	O
a	O
combination	O
of	O
structural	O
,	O
biophysical	B:C0005553
,	O
and	O
modelling	O
approaches	O
.	O

To	O
investigate	O
the	O
selectivity	O
of	O
these	O
inhibitors	O
we	O
used	O
a	O
combination	O
of	O
structural	O
,	O
biophysical	O
,	O
and	O
modelling	B:C0600115
approaches	O
.	O

We	O
determined	O
the	O
crystal	B:C0444626
structures	I:C0444626
of	O
the	O
CDK7	O
-	O
selective	O
compounds	O
ICEC0942	O
and	O
ICEC0943	O
bound	O
to	O
CDK2	O
,	O
and	O
used	O
these	O
to	O
build	O
models	O
of	O
inhibitor	O
binding	O
to	O
CDK7	O
.	O

We	O
determined	O
the	O
crystal	O
structures	I:C0444626
of	O
the	O
CDK7	B:C0255652
-	O
selective	O
compounds	O
ICEC0942	O
and	O
ICEC0943	O
bound	O
to	O
CDK2	O
,	O
and	O
used	O
these	O
to	O
build	O
models	O
of	O
inhibitor	O
binding	O
to	O
CDK7	O
.	O

We	O
determined	O
the	O
crystal	O
structures	I:C0444626
of	O
the	O
CDK7	O
-	O
selective	O
compounds	B:C1254351
ICEC0942	O
and	O
ICEC0943	O
bound	O
to	O
CDK2	O
,	O
and	O
used	O
these	O
to	O
build	O
models	O
of	O
inhibitor	O
binding	O
to	O
CDK7	O
.	O

We	O
determined	O
the	O
crystal	O
structures	I:C0444626
of	O
the	O
CDK7	O
-	O
selective	O
compounds	O
ICEC0942	B:C1254351
and	O
ICEC0943	O
bound	O
to	O
CDK2	O
,	O
and	O
used	O
these	O
to	O
build	O
models	O
of	O
inhibitor	O
binding	O
to	O
CDK7	O
.	O

We	O
determined	O
the	O
crystal	O
structures	I:C0444626
of	O
the	O
CDK7	O
-	O
selective	O
compounds	O
ICEC0942	O
and	O
ICEC0943	B:C1254351
bound	O
to	O
CDK2	O
,	O
and	O
used	O
these	O
to	O
build	O
models	O
of	O
inhibitor	O
binding	O
to	O
CDK7	O
.	O

We	O
determined	O
the	O
crystal	O
structures	I:C0444626
of	O
the	O
CDK7	O
-	O
selective	O
compounds	O
ICEC0942	O
and	O
ICEC0943	O
bound	O
to	O
CDK2	B:C0108855
,	O
and	O
used	O
these	O
to	O
build	O
models	O
of	O
inhibitor	O
binding	O
to	O
CDK7	O
.	O

We	O
determined	O
the	O
crystal	O
structures	I:C0444626
of	O
the	O
CDK7	O
-	O
selective	O
compounds	O
ICEC0942	O
and	O
ICEC0943	O
bound	O
to	O
CDK2	O
,	O
and	O
used	O
these	O
to	O
build	O
models	B:C0026344
of	O
inhibitor	O
binding	O
to	O
CDK7	O
.	O

We	O
determined	O
the	O
crystal	O
structures	I:C0444626
of	O
the	O
CDK7	O
-	O
selective	O
compounds	O
ICEC0942	O
and	O
ICEC0943	O
bound	O
to	O
CDK2	O
,	O
and	O
used	O
these	O
to	O
build	O
models	O
of	O
inhibitor	B:C0014432
binding	O
to	O
CDK7	O
.	O

We	O
determined	O
the	O
crystal	O
structures	I:C0444626
of	O
the	O
CDK7	O
-	O
selective	O
compounds	O
ICEC0942	O
and	O
ICEC0943	O
bound	O
to	O
CDK2	O
,	O
and	O
used	O
these	O
to	O
build	O
models	O
of	O
inhibitor	O
binding	O
to	O
CDK7	B:C0255652
.	O

Molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
of	O
inhibitors	B:C0014432
bound	O
to	O
CDK2	O
and	O
CDK7	O
generated	O
possible	O
models	O
of	O
inhibitor	O
binding	O
.	O

Molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
of	O
inhibitors	O
bound	O
to	O
CDK2	B:C0108855
and	O
CDK7	O
generated	O
possible	O
models	O
of	O
inhibitor	O
binding	O
.	O

Molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
of	O
inhibitors	O
bound	O
to	O
CDK2	O
and	O
CDK7	B:C0255652
generated	O
possible	O
models	O
of	O
inhibitor	O
binding	O
.	O

Molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
of	O
inhibitors	O
bound	O
to	O
CDK2	O
and	O
CDK7	O
generated	O
possible	O
models	B:C0026344
of	O
inhibitor	O
binding	O
.	O

Molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
of	O
inhibitors	O
bound	O
to	O
CDK2	O
and	O
CDK7	O
generated	O
possible	O
models	O
of	O
inhibitor	B:C0014432
binding	O
.	O

To	O
experimentally	B:C0681814
validate	O
these	O
models	O
,	O
we	O
gathered	O
isothermal	O
titration	O
calorimetry	O
(	O
ITC	O
)	O
binding	O
data	O
for	O
recombinant	O
wild	O
-	I:C1883559
type	I:C1883559
and	O
binding	O
site	I:C0005456
mutants	O
of	O
CDK7	O
and	O
CDK2	O
.	O

To	O
experimentally	O
validate	O
these	O
models	B:C0026344
,	O
we	O
gathered	O
isothermal	O
titration	O
calorimetry	O
(	O
ITC	O
)	O
binding	O
data	O
for	O
recombinant	O
wild	O
-	I:C1883559
type	I:C1883559
and	O
binding	O
site	I:C0005456
mutants	O
of	O
CDK7	O
and	O
CDK2	O
.	O

To	O
experimentally	O
validate	O
these	O
models	O
,	O
we	O
gathered	O
isothermal	O
titration	O
calorimetry	O
(	O
ITC	O
)	O
binding	O
data	O
for	O
recombinant	B:C0034861
wild	O
-	I:C1883559
type	I:C1883559
and	O
binding	O
site	I:C0005456
mutants	O
of	O
CDK7	O
and	O
CDK2	O
.	O

To	O
experimentally	O
validate	O
these	O
models	O
,	O
we	O
gathered	O
isothermal	O
titration	O
calorimetry	O
(	O
ITC	O
)	O
binding	O
data	O
for	O
recombinant	O
wild	B:C1883559
-	I:C1883559
type	I:C1883559
and	O
binding	O
site	I:C0005456
mutants	O
of	O
CDK7	O
and	O
CDK2	O
.	O

To	O
experimentally	O
validate	O
these	O
models	O
,	O
we	O
gathered	O
isothermal	O
titration	O
calorimetry	O
(	O
ITC	O
)	O
binding	O
data	O
for	O
recombinant	O
wild	O
-	I:C1883559
type	I:C1883559
and	O
binding	B:C0005456
site	I:C0005456
mutants	O
of	O
CDK7	O
and	O
CDK2	O
.	O

To	O
experimentally	O
validate	O
these	O
models	O
,	O
we	O
gathered	O
isothermal	O
titration	O
calorimetry	O
(	O
ITC	O
)	O
binding	O
data	O
for	O
recombinant	O
wild	O
-	I:C1883559
type	I:C1883559
and	O
binding	O
site	I:C0005456
mutants	B:C1564139
of	O
CDK7	O
and	O
CDK2	O
.	O

To	O
experimentally	O
validate	O
these	O
models	O
,	O
we	O
gathered	O
isothermal	O
titration	O
calorimetry	O
(	O
ITC	O
)	O
binding	O
data	O
for	O
recombinant	O
wild	O
-	I:C1883559
type	I:C1883559
and	O
binding	O
site	I:C0005456
mutants	O
of	O
CDK7	B:C0255652
and	O
CDK2	O
.	O

To	O
experimentally	O
validate	O
these	O
models	O
,	O
we	O
gathered	O
isothermal	O
titration	O
calorimetry	O
(	O
ITC	O
)	O
binding	O
data	O
for	O
recombinant	O
wild	O
-	I:C1883559
type	I:C1883559
and	O
binding	O
site	I:C0005456
mutants	O
of	O
CDK7	O
and	O
CDK2	B:C0108855
.	O

We	O
identified	O
specific	O
residues	O
of	O
CDK7	B:C0255652
,	O
notably	O
Asp155	O
,	O
that	O
are	O
involved	O
in	O
determining	O
inhibitor	O
selectivity	O
.	O

We	O
identified	O
specific	O
residues	O
of	O
CDK7	O
,	O
notably	O
Asp155	B:C0004015
,	O
that	O
are	O
involved	O
in	O
determining	O
inhibitor	O
selectivity	O
.	O

We	O
identified	O
specific	O
residues	O
of	O
CDK7	O
,	O
notably	O
Asp155	O
,	O
that	O
are	O
involved	O
in	O
determining	O
inhibitor	B:C0014432
selectivity	O
.	O

Our	O
MD	O
simulations	O
also	O
show	O
that	O
the	O
flexibility	O
of	O
the	O
G-	O
rich	O
and	O
activation	O
loops	O
of	O
CDK7	B:C0255652
is	O
likely	O
an	O
important	O
determinant	O
of	O
inhibitor	O
specificity	O
similar	O
to	O
CDK2	O
.	O

Our	O
MD	O
simulations	O
also	O
show	O
that	O
the	O
flexibility	O
of	O
the	O
G-	O
rich	O
and	O
activation	O
loops	O
of	O
CDK7	O
is	O
likely	O
an	O
important	O
determinant	O
of	O
inhibitor	B:C0014432
specificity	O
similar	O
to	O
CDK2	O
.	O

Our	O
MD	O
simulations	O
also	O
show	O
that	O
the	O
flexibility	O
of	O
the	O
G-	O
rich	O
and	O
activation	O
loops	O
of	O
CDK7	O
is	O
likely	O
an	O
important	O
determinant	O
of	O
inhibitor	O
specificity	O
similar	O
to	O
CDK2	B:C0108855
.	O

